

**Formulary Motion History
Topical Testosterone Products**

Drugs Reviewed	Motion	Date Reviewed	Motion & Second	Decision
Androderm Androgel Axiron Fortesta Striant Testim Testopel	After reviewing the clinical information for the drugs within the topical testosterone drug class, I move that no single drug or combination drug product in this class has a significant, clinically meaningful therapeutic advantage in terms of safety, efficacy, or clinical outcome for the treatment of hypogonadism. No product within the topical testosterone class will be excluded from the Washington Medicaid Formulary.	June 20, 2012	Barak Smith	Passed Unanimous